Journal Home
Search for

Volume 13, Issue 1, Pages 77-83 (January 2010)


View previous. 12 of 105 View next.

Quantitative Ultrasound and Dual-Energy X-ray Absorptiometry in Children and Adolescents With Neurofibromatosis of Type 1

Carla Caffarelli1, Stefano Gonnelli1Corresponding Author Informationemail address, Loredana Tanzilli1, Rossella Vivarelli2, Silvia Tamburello2, Paolo Balestri2, Ranuccio Nuti1

Received 26 March 2009; received in revised form 22 October 2009; accepted 24 October 2009.

Abstract 

Reduced areal bone mineral density (aBMD) is a common feature of neurofibromatosis type 1 (NF1). Moreover, in recent years there has been a growing interest in using quantitative ultrasound (QUS) for the evaluation of bone status. In 55 NF1 subjects (mean age: 9.3±5.4yr) and in 51 age- and sex-matched controls we measured aBMD at lumbar spine, at femoral neck (aBMD-FN), and at total femur (aBMD-T). Apparent volumetric bone mineral density (BMAD) was also calculated. In all subjects, QUS parameters at phalanges were evaluated. In NF1 subjects, the values of aBMD and BMAD were lower than in controls at all skeletal sites, but the difference reached statistical significance only at femoral sites (p<0.05). Both aBMD and QUS parameters were lower in those NF1 subjects with skeletal abnormalities than in those without abnormalities, but the difference was statistically significant (p<0.05) only for aBMD-FN and aBMD-T. Multiple regression analysis showed that the subjects with skeletal abnormalities had a higher risk of having bone transmission time (BTT) Z-score and aBMD Z-score at femoral sites less than −1. In conclusion, our results suggest that aBMD and QUS represent useful tools in evaluating the impairment of bone status in NF1 subjects.

1 Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Siena, Italy

2 Department of Pediatrics, Obstetrics, and Reproductive Medicine, University of Siena, Siena, Italy

Corresponding Author InformationAddress correspondence to: Stefano Gonnelli, MD, Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100 Siena, Italy.

PII: S1094-6950(09)00264-9

doi:10.1016/j.jocd.2009.10.002


View previous. 12 of 105 View next.